| Old Articles: <Older 7151-7160 Newer> |
|---|
 |
The Motley Fool
February 8, 2011
Brian Orelli |
What Will Intuitive Surgical Do for an Encore? Intuitive Surgical managed just a 10% year-over-year increase in revenue from sales of its da Vinci Surgical Systems in the fourth quarter of last year. Yet its total revenue increased a solid 21%. How?   |
The Motley Fool
February 8, 2011
Travis Hoium |
RehabCare and Kindred Healthcare Shares Popped: What You Need to Know Shares of post-acute-care service provider RehabCare Group zoomed 43% higher today after the company announced it was being bought out by Kindred Healthcare |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Ready for the Biotech Century: Where's the Smart Money Going? Here's a list of four biotech stocks seeing significant institutional buying and insider buying over the last three months: Codexis... Chelsea Therapeutics... Exact Sciences... ZIOPHARM... |
The Motley Fool
February 7, 2011
Brian Orelli |
Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet. |
The Motley Fool
February 7, 2011
Dan Dzombak |
Lincare's Management Is Creating Value What economic value added momentum shows us about this company's leadership. |
The Motley Fool
February 7, 2011
Dan Dzombak |
Advisory Board's Management Is Creating Value What economic value added momentum shows us about this company's leadership. |
The Motley Fool
February 7, 2011
Jordan DiPietro |
7 Cheap Health-Care Stocks Paying Cold, Hard Cash These health-care stocks are trading cheap and paying good dividends. |
Pharmaceutical Executive
February 4, 2011
William Looney |
The Night Stalkers: Keeping CEOs Awake in 2011 The consensus is that 2011 will be a bad year for Big Pharma. Let's inventory a few of the 'night stalkers -- issues that are likely to keep members of the C-suite awake beyond a sensible 'lights out' time. |
The Motley Fool
February 4, 2011
Brian Orelli |
Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you? |
The Motley Fool
February 4, 2011
Seth Jayson |
Does Edwards Lifesciences Measure Up? With recent TTM operating margins exceeding historical averages, Edwards Lifesciences looks like it's doing fine. |
| <Older 7151-7160 Newer> Return to current articles. |
